MX387909B - Tratamiento para la migra?a - Google Patents

Tratamiento para la migra?a

Info

Publication number
MX387909B
MX387909B MX2019014784A MX2019014784A MX387909B MX 387909 B MX387909 B MX 387909B MX 2019014784 A MX2019014784 A MX 2019014784A MX 2019014784 A MX2019014784 A MX 2019014784A MX 387909 B MX387909 B MX 387909B
Authority
MX
Mexico
Prior art keywords
migraine
leucine
treatment
acetyl
treating
Prior art date
Application number
MX2019014784A
Other languages
English (en)
Spanish (es)
Other versions
MX2019014784A (es
Inventor
Mallory Factor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX387909(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2019014784A publication Critical patent/MX2019014784A/es
Publication of MX387909B publication Critical patent/MX387909B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019014784A 2017-06-14 2018-06-25 Tratamiento para la migra?a MX387909B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (2)

Publication Number Publication Date
MX2019014784A MX2019014784A (es) 2021-11-16
MX387909B true MX387909B (es) 2025-03-19

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014784A MX387909B (es) 2017-06-14 2018-06-25 Tratamiento para la migra?a

Country Status (25)

Country Link
US (1) US11471434B2 (enExample)
EP (1) EP3638370B1 (enExample)
JP (1) JP7130739B2 (enExample)
KR (1) KR102594130B1 (enExample)
CN (1) CN111093772B (enExample)
AU (1) AU2018284330B2 (enExample)
CY (1) CY1123860T1 (enExample)
DK (1) DK3638370T3 (enExample)
ES (1) ES2847169T3 (enExample)
GB (1) GB201709459D0 (enExample)
HR (1) HRP20210108T1 (enExample)
HU (1) HUE053089T2 (enExample)
IL (1) IL271211B2 (enExample)
LT (1) LT3638370T (enExample)
MA (1) MA49396B1 (enExample)
MD (1) MD3638370T2 (enExample)
MX (1) MX387909B (enExample)
PL (1) PL3638370T3 (enExample)
PT (1) PT3638370T (enExample)
RS (1) RS61481B1 (enExample)
SG (1) SG11201912146RA (enExample)
SI (1) SI3638370T1 (enExample)
SM (1) SMT202100037T1 (enExample)
WO (1) WO2018229738A1 (enExample)
ZA (1) ZA201908087B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3091353A1 (en) * 2018-02-15 2019-08-22 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
BR112021010923A2 (pt) 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
EP2080757A1 (en) * 2003-07-24 2009-07-22 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
DE602004017481D1 (de) * 2003-09-22 2008-12-11 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
PT2017276E (pt) * 2003-09-22 2011-04-05 Euro Celtique Sa Compostos de fenilcarboxamida úteis para o tratamento da dor
CN1902178A (zh) * 2003-12-30 2007-01-24 欧洲凯尔特公司 用于治疗疼痛的哌嗪
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP5876423B2 (ja) * 2010-06-22 2016-03-02 塩野義製薬株式会社 Ｔｒｐｖ１阻害活性を有する化合物とその使用
EP2588130B1 (en) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
EP3536368B1 (en) * 2010-11-09 2025-09-17 MannKind Corporation Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
AU2012293417A1 (en) * 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2017182802A1 (en) 2016-04-19 2017-10-26 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
KR102467953B1 (ko) 2016-08-11 2022-11-16 인트라바이오 리미티드 리소좀 축적 질환과 관련된 약제 조성물 및 용도
MA43828B1 (fr) 2016-08-11 2019-09-30 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
WO2018178670A1 (en) 2017-03-28 2018-10-04 Intrabio Ltd Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
MA50399A (fr) 2017-10-18 2020-08-26 Intrabio Ltd Agents thérapeutiques pour mobilité et fonction cognitive améliorées et pour le traitement de maladies neurodégénératives et de troubles de stockage lysosomal
SG11202003390UA (en) 2017-10-18 2020-05-28 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
CA3091353A1 (en) 2018-02-15 2019-08-22 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
BR112021010923A2 (pt) 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina
KR20250171484A (ko) 2019-03-02 2025-12-08 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
US20220362189A1 (en) 2019-06-28 2022-11-17 Intrabio Ltd. Combination therapy with acetyl-leucine and miglustat
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Also Published As

Publication number Publication date
JP2020526575A (ja) 2020-08-31
SI3638370T1 (sl) 2021-04-30
IL271211A (en) 2020-01-30
WO2018229738A1 (en) 2018-12-20
MX2019014784A (es) 2021-11-16
US20200253905A1 (en) 2020-08-13
KR102594130B1 (ko) 2023-10-24
IL271211B1 (en) 2023-09-01
EP3638370A1 (en) 2020-04-22
PT3638370T (pt) 2021-01-26
MA49396A (fr) 2020-04-22
EP3638370B1 (en) 2020-11-11
KR20210013518A (ko) 2021-02-04
HRP20210108T1 (hr) 2021-03-19
US11471434B2 (en) 2022-10-18
CY1123860T1 (el) 2022-05-27
CN111093772A (zh) 2020-05-01
SG11201912146RA (en) 2020-01-30
LT3638370T (lt) 2021-03-25
AU2018284330A1 (en) 2020-01-02
HUE053089T2 (hu) 2021-06-28
DK3638370T3 (da) 2021-01-25
GB201709459D0 (en) 2017-07-26
SMT202100037T1 (it) 2021-03-15
RS61481B1 (sr) 2021-03-31
RU2020100475A (ru) 2021-07-14
CN111093772B (zh) 2023-11-03
IL271211B2 (en) 2024-01-01
ZA201908087B (en) 2024-11-27
CA3067321A1 (en) 2018-12-20
JP7130739B2 (ja) 2022-09-05
RU2020100475A3 (enExample) 2021-10-22
BR112019026660A2 (pt) 2020-07-14
PL3638370T3 (pl) 2021-05-17
MA49396B1 (fr) 2021-03-31
ES2847169T3 (es) 2021-08-02
AU2018284330B2 (en) 2024-03-14
MD3638370T2 (ro) 2021-04-30

Similar Documents

Publication Publication Date Title
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
MX387115B (es) Métodos para tratar la influenza.
ZA202409975B (en) Methods of treating schizophrenia
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2022001863A (es) Metodos para tratar los tumores del estroma gastrointestinal.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX2025009723A (es) Metodos de tratamiento contra adicciones
PH12020551586A1 (en) Oxysterols and methods of use thereof
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX381311B (es) Método para el tratamiento de prurito y/o comezón.
ZA201908087B (en) Treatment for migraine
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MY205171A (en) Methods of treatment of hypertriglyceridemia
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
ZA202004849B (en) Therapeutic agents for treating restless legs syndrome
MX374354B (es) Método de curación de heridas.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
MX2017013453A (es) Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica.
MX2021001394A (es) Metodo para mejorar la eficacia de un agente anticanceroso.